NASDAQ:NBIX - Neurocrine Biosciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $113.60
  • Forecasted Upside: 7.55 %
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.75 (0.72%)

This chart shows the closing price for NBIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neurocrine Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBIX

Analyst Price Target is $113.60
▲ +7.55% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Neurocrine Biosciences in the last 3 months. The average price target is $113.60, with a high forecast of $154.00 and a low forecast of $76.00. The average price target represents a 7.55% upside from the last price of $105.63.

This chart shows the closing price for NBIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 17 contributing investment analysts is to hold stock in Neurocrine Biosciences. This rating has held steady since February 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2022MizuhoBoost Price TargetNeutral$95.00 ➝ $98.00Low
8/5/2022Robert W. BairdBoost Price Target$117.00 ➝ $125.00Low
8/5/2022BarclaysBoost Price TargetOverweight$110.00 ➝ $113.00Low
7/15/2022Morgan StanleyBoost Price TargetEqual Weight$100.00 ➝ $102.00Low
4/28/2022WedbushReiterated RatingOutperformHigh
4/12/2022BarclaysBoost Price TargetOverweight$100.00 ➝ $110.00Medium
4/4/2022JPMorgan Chase & Co.Boost Price TargetOverweight$125.00 ➝ $126.00Low
3/3/2022Jefferies Financial GroupDowngradeHold$94.00Medium
3/3/2022Piper SandlerDowngradeOverweight ➝ Neutral$114.00 ➝ $94.00High
2/24/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$115.00Low
2/14/2022HC WainwrightReiterated RatingBuy$140.00Low
2/14/2022Morgan StanleyBoost Price TargetEqual Weight$95.00 ➝ $100.00Medium
2/14/2022MizuhoLower Price Target$103.00 ➝ $95.00Medium
2/11/2022Raymond JamesReiterated RatingBuy$125.00Medium
2/1/2022Morgan StanleyLower Price TargetEqual Weight$103.00 ➝ $95.00Low
1/26/2022Piper SandlerLower Price Target$123.00 ➝ $114.00Low
1/20/2022BarclaysLower Price TargetOverweight$110.00 ➝ $100.00Low
1/18/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$122.00 ➝ $90.00High
1/7/2022HC WainwrightReiterated RatingBuy$140.00High
1/7/2022Morgan StanleyLower Price TargetEqual Weight$112.00 ➝ $103.00High
12/8/2021HC WainwrightReiterated RatingBuy$139.00Low
12/8/2021OppenheimerBoost Price TargetOutperform ➝ Outperform$140.00 ➝ $154.00High
12/8/2021CitigroupBoost Price TargetBuy ➝ Buy$127.00 ➝ $129.00High
11/18/2021BMO Capital MarketsInitiated CoverageUnderperform$76.00Low
11/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$124.00Low
11/2/2021CitigroupLower Price TargetBuy$132.00 ➝ $127.00High
11/2/2021Raymond JamesLower Price TargetOutperform$163.00 ➝ $150.00High
11/2/2021Royal Bank of CanadaLower Price TargetOutperform$130.00 ➝ $119.00High
11/2/2021MizuhoBoost Price TargetNeutral$99.00 ➝ $103.00High
11/2/2021Cantor FitzgeraldBoost Price TargetOverweight$117.00 ➝ $123.00High
10/18/2021SVB LeerinkReiterated RatingMarket PerformLow
10/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$110.00 ➝ $112.00Low
9/30/2021HC WainwrightReiterated RatingBuyHigh
9/22/2021Needham & Company LLCInitiated CoverageHoldLow
8/4/2021Morgan StanleyLower Price TargetOverweight$116.00 ➝ $110.00High
7/16/2021HC WainwrightReiterated RatingBuy$140.00Medium
5/18/2021The Goldman Sachs GroupInitiated CoverageNeutral$108.00Low
5/6/2021WedbushLower Price Target$112.00 ➝ $107.00Medium
5/6/2021OppenheimerLower Price Target$145.00 ➝ $140.00High
5/6/2021Morgan StanleyLower Price TargetOverweight$125.00 ➝ $116.00High
5/6/2021SVB LeerinkLower Price TargetMarket Perform$110.00 ➝ $100.00High
5/6/2021BarclaysUpgradeEqual Weight ➝ Overweight$110.00High
5/3/2021MizuhoLower Price TargetNeutral$119.00 ➝ $116.00N/A
4/26/2021MizuhoLower Price TargetIn-Line ➝ Neutral$119.00 ➝ $116.00High
4/19/2021Morgan StanleyBoost Price TargetOverweight$121.00 ➝ $125.00Low
4/12/2021WedbushLower Price TargetOutperform$126.00 ➝ $112.00Medium
3/5/2021Robert W. BairdReiterated RatingBuyHigh
2/5/2021MizuhoBoost Price TargetNeutral$117.00 ➝ $119.00High
2/1/2021Raymond JamesInitiated CoverageOutperform$163.00 ➝ $163.00Low
1/26/2021William BlairReiterated RatingBuyMedium
12/29/2020Cantor FitzgeraldLower Price TargetOverweight$168.00 ➝ $121.00N/A
12/16/2020Morgan StanleyLower Price TargetOverweight$133.00 ➝ $121.00Medium
12/7/2020WedbushLower Price TargetOutperform$129.00 ➝ $121.00High
11/10/2020OppenheimerLower Price Target$150.00 ➝ $145.00Medium
11/10/2020Smith Barney CitigroupLower Price Target$149.00 ➝ $138.00Low
11/10/2020William BlairReiterated RatingOutperformLow
11/10/2020WedbushLower Price TargetOutperform$147.00 ➝ $129.00Medium
11/10/2020Credit Suisse GroupLower Price TargetNeutral$105.00 ➝ $90.00High
11/10/2020MizuhoLower Price TargetNeutral$132.00 ➝ $117.00High
11/10/2020SVB LeerinkLower Price TargetMarket Perform$120.00 ➝ $100.00High
10/29/2020OppenheimerLower Price TargetOutperform$155.00 ➝ $150.00Low
9/30/2020BenchmarkInitiated CoverageHoldHigh
8/4/2020Credit Suisse GroupLower Price TargetNeutral$135.00 ➝ $126.00High
8/4/2020Morgan StanleyLower Price TargetOverweight$149.00 ➝ $146.00High
8/4/2020HC WainwrightBoost Price TargetBuy$131.00 ➝ $140.00High
8/4/2020Cantor FitzgeraldBoost Price TargetOverweight$144.00 ➝ $161.00High
8/4/2020MizuhoBoost Price TargetNeutral$127.00 ➝ $132.00High
8/4/2020SVB LeerinkBoost Price TargetMarket Perform$105.00 ➝ $120.00High
8/4/2020Piper SandlerBoost Price TargetOverweight$141.00 ➝ $145.00High
8/4/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$136.00High
7/23/2020MizuhoBoost Price TargetNeutral$105.00 ➝ $127.00Medium
7/20/2020Credit Suisse GroupBoost Price TargetNeutral$101.00 ➝ $135.00Medium
7/17/2020OppenheimerBoost Price TargetOutperform$142.00 ➝ $152.00Medium
7/15/2020Morgan StanleyBoost Price TargetOverweight$120.00 ➝ $149.00Low
6/29/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$135.00High
6/26/2020CitigroupBoost Price TargetBuy$124.00 ➝ $149.00High
6/18/2020JPMorgan Chase & Co.Boost Price TargetIn-Line ➝ Overweight$122.00 ➝ $134.00Medium
6/18/2020Royal Bank of CanadaBoost Price TargetOutperform$116.00 ➝ $135.00Low
6/17/2020HC WainwrightReiterated RatingBuy$125.00 ➝ $131.00Low
6/16/2020Needham & Company LLCInitiated CoverageHoldLow
6/16/2020OppenheimerInitiated CoverageBuy$142.00Low
6/8/2020WedbushInitiated CoverageOutperform$147.00Low
6/1/2020Piper SandlerReiterated RatingBuy$126.00Low
5/7/2020BarclaysBoost Price TargetEqual Weight$105.00 ➝ $108.00High
5/7/2020MizuhoBoost Price TargetNeutral$103.00 ➝ $105.00High
5/7/2020Morgan StanleyLower Price TargetBuy$121.00 ➝ $120.00High
5/7/2020HC WainwrightReiterated RatingBuy$125.00High
5/7/2020Needham & Company LLCReiterated RatingHoldHigh
4/30/2020William BlairReiterated RatingBuyHigh
4/27/2020Needham & Company LLCReiterated RatingHoldMedium
4/13/2020OppenheimerLower Price TargetOutperform$132.00 ➝ $130.00Low
4/8/2020Piper SandlerLower Price Target$147.00 ➝ $125.00Medium
4/8/2020Needham & Company LLCReiterated RatingHold ➝ NeutralMedium
4/8/2020Royal Bank of CanadaReiterated RatingBuy$104.00Medium
3/5/2020CitigroupInitiated CoverageBuy$124.00Medium
2/27/2020BarclaysInitiated CoverageEqual Weight$105.00High
2/24/2020William BlairInitiated CoverageOutperform$116.00High
2/14/2020Stifel NicolausReiterated RatingBuy$127.00N/A
2/5/2020MizuhoInitiated CoverageNeutral$107.00Low
2/5/2020HC WainwrightReiterated RatingBuy$102.00 ➝ $125.00Medium
1/20/2020Royal Bank of CanadaReiterated RatingBuy$125.00Low
1/17/2020Morgan StanleyBoost Price TargetOverweight$120.00 ➝ $121.00Medium
1/13/2020OppenheimerBoost Price TargetOutperform$115.00 ➝ $132.00High
12/17/2019Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $120.00Medium
12/13/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$110.00Low
12/12/2019Piper Jaffray CompaniesReiterated RatingOverweight$116.00 ➝ $153.00Medium
11/5/2019Piper Jaffray CompaniesBoost Price Target$111.00 ➝ $116.00Low
9/6/2019Royal Bank of CanadaSet Price TargetBuy$118.00Medium
8/7/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$118.00Low
7/31/2019Needham & Company LLCReiterated RatingHoldMedium
7/30/2019Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $110.00High
7/30/2019Piper Jaffray CompaniesBoost Price TargetOverweight$103.00 ➝ $111.00High
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$100.00Low
7/16/2019OppenheimerInitiated CoverageOutperform$100.00Low
7/15/2019Stifel NicolausSet Price TargetBuy$113.00Low
6/4/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$88.00Medium
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$95.00Medium
4/22/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$100.00 ➝ $106.00High
4/11/2019Evercore ISIInitiated CoverageOutperformLow
3/29/2019BarclaysReiterated RatingBuy$110.00High
3/13/2019OppenheimerBoost Price TargetOutperform$105.00 ➝ $110.00Medium
2/6/2019Bank of AmericaLower Price TargetBuy$124.00 ➝ $117.00Medium
2/6/2019Cantor FitzgeraldReiterated RatingOverweightHigh
1/30/2019HC WainwrightReiterated RatingBuyMedium
1/29/2019Cantor FitzgeraldReiterated RatingBuy$121.00Medium
1/29/2019OppenheimerSet Price TargetBuy$105.00Medium
1/24/2019Needham & Company LLCDowngradeBuy ➝ HoldLow
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$97.00 ➝ $100.00Medium
1/15/2019HC WainwrightReiterated RatingBuy$102.00High
1/6/2019OppenheimerSet Price TargetBuy$105.00High
12/13/2018OppenheimerLower Price TargetOutperform$140.00 ➝ $105.00Low
12/13/2018JPMorgan Chase & Co.Lower Price TargetOverweight$127.00 ➝ $97.00Low
12/13/2018Robert W. BairdLower Price TargetOutperform$131.00 ➝ $96.00Medium
12/13/2018SVB LeerinkLower Price TargetMarket Perform$110.00 ➝ $84.00Medium
12/13/2018HC WainwrightReiterated RatingBuy$162.00Medium
12/13/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$103.00Medium
12/13/2018BarclaysReiterated RatingBuy$95.00Medium
12/12/2018Stifel NicolausLower Price TargetBuy$115.00 ➝ $17.07High
12/12/2018Cantor FitzgeraldReiterated RatingBuy$121.00High
12/12/2018Needham & Company LLCSet Price TargetBuy$104.00High
12/11/2018OppenheimerSet Price TargetBuy$140.00High
12/5/2018Cantor FitzgeraldSet Price TargetBuy$150.00Low
11/12/2018SVB LeerinkInitiated CoverageMarket Perform$110.00High
11/6/2018Morgan StanleyLower Price TargetOverweight ➝ Buy$145.00 ➝ $135.00Low
11/6/2018Piper Jaffray CompaniesSet Price TargetBuy$111.00High
11/5/2018Cantor FitzgeraldSet Price TargetBuy$150.00High
11/5/2018OppenheimerSet Price TargetBuy$140.00High
10/5/2018Piper Jaffray CompaniesSet Price TargetBuy$115.00Low
9/20/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$137.00 ➝ $142.00Low
9/20/2018Cantor FitzgeraldSet Price TargetBuy$150.00Low
9/14/2018Cantor FitzgeraldInitiated CoverageBuy$150.00Low
9/12/2018OppenheimerSet Price TargetBuy$140.00Low
9/10/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$145.00Medium
9/4/2018ICAPLower Price TargetOutperform$140.00 ➝ $128.00Medium
9/4/2018OppenheimerSet Price TargetBuy$140.00Medium
8/22/2018Cantor FitzgeraldInitiated CoverageOverweight$150.00Low
8/7/2018Stifel NicolausInitiated CoverageBuy$137.00Low
8/1/2018Needham & Company LLCSet Price TargetBuy$125.00Low
8/1/2018HC WainwrightReiterated RatingBuy$162.00High
8/1/2018BarclaysBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $135.00High
7/31/2018OppenheimerSet Price TargetBuy$128.00High
7/30/2018Jefferies Financial GroupBoost Price TargetBuy$124.00High
7/25/2018Robert W. BairdReiterated RatingOutperform ➝ Outperform$100.00 ➝ $122.00High
7/16/2018JPMorgan Chase & Co.Boost Price TargetOverweight$127.00Medium
6/8/2018BarclaysSet Price TargetBuy$100.00Low
5/14/2018OppenheimerSet Price TargetBuy$120.00Low
5/7/2018CowenReiterated RatingBuy$100.00Low
5/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$101.00 ➝ $102.00High
5/1/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$97.00 ➝ $99.00High
5/1/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$100.00 ➝ $103.00High
5/1/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$84.00 ➝ $100.00High
4/10/2018OppenheimerSet Price TargetBuy$110.00High
3/21/2018OppenheimerReiterated RatingBuyLow
3/14/2018Piper Jaffray CompaniesReiterated RatingOverweight$113.00Medium
3/13/2018OppenheimerSet Price TargetBuy$110.00Medium
2/22/2018OppenheimerSet Price TargetBuy$110.00Low
2/22/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00 ➝ $110.00Low
2/20/2018SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $96.00Medium
2/14/2018Deutsche Bank AktiengesellschaftBoost Price TargetBuy$97.00Medium
2/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$79.00 ➝ $100.00High
2/14/2018BarclaysReiterated RatingOverweight$100.00High
2/14/2018OppenheimerSet Price TargetBuy$95.00 ➝ $100.00High
1/16/2018Needham & Company LLCBoost Price TargetBuy$95.00High
1/15/2018OppenheimerSet Price TargetBuy$85.00 ➝ $95.00High
1/5/2018Jefferies Financial GroupBoost Price TargetBuy$105.00Medium
12/12/2017OppenheimerSet Price TargetBuy$85.00Low
11/14/2017OppenheimerSet Price TargetBuy$85.00N/A
11/3/2017Robert W. BairdReiterated RatingBuy$84.00N/A
11/2/2017Needham & Company LLCReiterated RatingBuy$86.00N/A
11/2/2017BarclaysBoost Price TargetOverweight$75.00 ➝ $85.00N/A
11/2/2017OppenheimerBoost Price TargetOutperform$70.00 ➝ $85.00N/A
11/2/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$79.00N/A
11/2/2017BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$83.00 ➝ $109.00N/A
11/2/2017SVB LeerinkReiterated RatingOutperform$72.00 ➝ $83.00N/A
11/2/2017CitigroupReiterated RatingBuy$79.00N/A
10/25/2017Piper Jaffray CompaniesReiterated RatingBuy$76.00N/A
10/10/2017SVB LeerinkReiterated RatingOutperform$67.00 ➝ $72.00N/A
10/5/2017BMO Capital MarketsReiterated RatingOutperform$84.00N/A
10/3/2017Jefferies Financial GroupReiterated RatingBuy$66.00 ➝ $69.00Low
9/21/2017Robert W. BairdReiterated RatingOutperform$66.00High
9/17/2017Needham & Company LLCReiterated RatingBuy$58.00Low
9/7/2017OppenheimerReiterated RatingBuy$70.00Low
8/24/2017Piper Jaffray CompaniesSet Price TargetBuy$68.00Medium
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 7 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 4 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $105.63
Low: $105.19
High: $106.96

50 Day Range

MA: $96.36
Low: $88.93
High: $107.66

52 Week Range

Now: $105.63
Low: $71.88
High: $109.26


1,233,794 shs

Average Volume

796,756 shs

Market Capitalization

$10.10 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Neurocrine Biosciences?

The following Wall Street sell-side analysts have issued research reports on Neurocrine Biosciences in the last twelve months: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada,, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Wedbush.
View the latest analyst ratings for NBIX.

What is the current price target for Neurocrine Biosciences?

15 Wall Street analysts have set twelve-month price targets for Neurocrine Biosciences in the last year. Their average twelve-month price target is $113.60, suggesting a possible upside of 7.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting NBIX will reach $154.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $76.00 for Neurocrine Biosciences in the next year.
View the latest price targets for NBIX.

What is the current consensus analyst rating for Neurocrine Biosciences?

Neurocrine Biosciences currently has 1 sell rating, 7 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NBIX, but not buy more shares or sell existing shares.
View the latest ratings for NBIX.

What other companies compete with Neurocrine Biosciences?

How do I contact Neurocrine Biosciences' investor relations team?

Neurocrine Biosciences' physical mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company's listed phone number is (858) 617-7600 and its investor relations email address is [email protected] The official website for Neurocrine Biosciences is Learn More about contacing Neurocrine Biosciences investor relations.